Johnson & Johnson vs VanEck Rare Earth/Strategic Metals — how do they compare? Johnson & Johnson trades at $260.51 (market cap $626.09B), while VanEck Rare Earth/Strategic Metals trades at $77.3. The key difference: Johnson & Johnson pays a 2.06% dividend while VanEck Rare Earth/Strategic Metals pays none, and Johnson & Johnson is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| JNJ | REMX | |
|---|---|---|
Market Cap | $626.09B | — |
Volume | 6,156,228 | — |
Sector | Health | Sector/Thematic |
52-Week High | $267.24 | $109.53 |
52-Week Low | $172.78 | $56.60 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $77.03, down 1.81% with a bullish technical signal from moving averages but neutral oscillators. The ETF provides exposure to 38 global rare earth companies, though key financial ratios remain undisclosed. Recent news highlights U.S. efforts to secure critical minerals supply chains amid China's export controls, with Energy Fuels expanding domestic production capacity.
Outlook hinges on geopolitical rare earth dynamics and U.S. supply chain independence initiatives. Risks include high volatility (~50% annualized) and China concentration. Analyst sentiment is mixed due to thematic reliance on policy shifts and commodity cycles, warranting caution for conservative investors.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →